Literature DB >> 10822133

Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines.

O Nagakawa1, K Murakami, T Yamaura, Y Fujiuchi, J Murata, H Fuse, I Saiki.   

Abstract

Membrane-type metalloproteinase-1 (MT1-MMP) is a transmembrane metalloproteinase, which activates proMMP-2 and expressed on the cell surface in many invasive cancer cells. We investigated the expression of MT1-MMP in prostate cancer cell lines. MT1-MMP protein and mRNA were expressed in PC-3, DU-145 and TSU-pr1 cells (androgen-independent prostate cancer cell lines), but in LNCaP cells (androgen-dependent prostate cancer cell line). MT1-MMP protein was negative and mRNA was low to detect by RT-PCR. Cell lysate of PC-3 cleaved proMMP-2 to the active form. In addition, both hepatocyte growth factor (HGF) and gastrin-releasing peptide (GRP) increased Matrigel invasion and induced the expression of MT1-MMP protein in DU-145 prostate cancer cells. These results suggest that MT1-MMP is indeed the tumor-specific activator of proMMP-2 in androgen-independent prostate cancer cells and plays an important role in the invasive properties of prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10822133     DOI: 10.1016/s0304-3835(00)00425-0

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  23 in total

1.  Metalloproteinase binding proteins: WO2009097397.

Authors:  Yoshifumi Itoh
Journal:  Expert Opin Ther Pat       Date:  2010-08       Impact factor: 6.674

2.  Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone.

Authors:  J Zhang; J Dai; Y Qi; D L Lin; P Smith; C Strayhorn; A Mizokami; Z Fu; J Westman; E T Keller
Journal:  J Clin Invest       Date:  2001-05       Impact factor: 14.808

3.  Membranous type matrix metalloproteinase 16 induces human prostate cancer metastasis.

Authors:  Chunwa Jiang; Juanjing Wang; Chen Dong; Wei Wei; Jiang Li; Xiaomeng Li
Journal:  Oncol Lett       Date:  2017-07-07       Impact factor: 2.967

4.  Re-expression of miR-200 by novel approaches regulates the expression of PTEN and MT1-MMP in pancreatic cancer.

Authors:  Omar Soubani; Azfur S Ali; Farah Logna; Shadan Ali; Philip A Philip; Fazlul H Sarkar
Journal:  Carcinogenesis       Date:  2012-05-27       Impact factor: 4.944

5.  Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase.

Authors:  Hoang-Lan Nguyen; Stanley Zucker; Kevin Zarrabi; Pournima Kadam; Cathleen Schmidt; Jian Cao
Journal:  Mol Cancer Res       Date:  2011-08-17       Impact factor: 5.852

6.  Quantitative proteomics profiling of murine mammary gland cells unravels impact of annexin-1 on DNA damage response, cell adhesion, and migration.

Authors:  Hannah L F Swa; Walter P Blackstock; Lina H K Lim; Jayantha Gunaratne
Journal:  Mol Cell Proteomics       Date:  2012-04-16       Impact factor: 5.911

7.  The metalloproteinase inhibitor TIMP-2 is down-regulated by androgens in LNCaP prostate carcinoma cells.

Authors:  Ase Bratland; Erlend Ragnhildstveit; Kristin Bjørnland; Kristin Andersen; Gunhild Mari Maelandsmo; Oystein Fodstad; Fahri Saatcioglu; Anne Hansen Ree
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

8.  Neuroendocrine differentiation in prostate cancer.

Authors:  Yin Sun; Junyang Niu; Jiaoti Huang
Journal:  Am J Transl Res       Date:  2009-02-05       Impact factor: 4.060

9.  Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells.

Authors:  Isis C Sroka; Raymond B Nagle; G Tim Bowden
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

10.  Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth.

Authors:  R Daniel Bonfil; Zhong Dong; J Carlos Trindade Filho; Aaron Sabbota; Pamela Osenkowski; Sanaa Nabha; Hamilto Yamamoto; Sreenivasa R Chinni; Huiren Zhao; Shahriar Mobashery; Robert L Vessella; Rafael Fridman; Michael L Cher
Journal:  Am J Pathol       Date:  2007-06       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.